<DOC>
	<DOCNO>NCT00473512</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose evaluate safety , tolerability , activity recommend dose ( maximum tolerate dose [ MTD ] ) abiraterone acetate ( also know CB7630 ) participants hormone refractory prostate ( gland make fluid aid movement sperm ) cancer ( HRPC ) .</brief_summary>
	<brief_title>A Safety Efficacy Study Abiraterone Acetate Participants With Prostate Cancer Who Have Failed Hormone Therapy</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) study evaluate safety , tolerability , recommend dose abiraterone acetate take orally ( mouth ) , daily participant HRPC . The study consist dose escalation stage ( Phase 1 ) conduct determine MTD abiraterone activity evaluation stage ( Phase 2 ) evaluate activity abiraterone participant HRPC . Escalated dose abiraterone ( start 250 milligram [ mg ] maximum 2000 mg ) give 28-day treatment period determine MTD . Participants give MTD abiraterone 12 cycle ( 28 day ) Phase 2 study . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically ( pertain disease status body tissue cell ) document adenocarcinoma prostate , clinically refractory ( respond treatment ) resistant hormone therapy , document progression follow least one hormonal therapy Prostate specific antigen ( PSA ) evidence progressive prostate cancer Participants withdrawn antiandrogen therapy le 6 month prior inclusion study require one PSA high last prewithdrawal PSA 2 increase PSA document postwithdrawal nadir ( value ) great equal 4 week treatment withdrawal treat flutamide great equal 6 week treat bicalutamide nilutamide Eastern Cooperative Oncology Group ( ECOG ) performance status score equal 0 1 Life expectancy great equal to12 week Participants central nervous system ( brain spinal cord ) disease and/or brain metastases No currently active second malignancy ( cancer progressively enlarge spread tumor ) nonmelanoma skin cancer Myocardial infarction within 6 month prior start study No active uncontrolled autoimmune disease ( disorder person 's immune system attack part body ) may require corticosteroid therapy protocol treatment Major surgery significant traumatic injury within 4 week start study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Abiraterone acetate</keyword>
	<keyword>CB7630</keyword>
	<keyword>Prostatic neoplasm</keyword>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>Castration resistant prostate cancer</keyword>
	<keyword>Castration refractory prostate cancer</keyword>
</DOC>